Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002961948 | SCV003280924 | uncertain significance | Pancreatic adenocarcinoma | 2022-10-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C65"). This variant has not been reported in the literature in individuals affected with PALLD-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.009%). This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 115 of the PALLD protein (p.Pro115Ser). |
Ambry Genetics | RCV004827919 | SCV005463937 | uncertain significance | not specified | 2024-12-01 | criteria provided, single submitter | clinical testing | The p.P115S variant (also known as c.343C>T), located in coding exon 1 of the PALLD gene, results from a C to T substitution at nucleotide position 343. The proline at codon 115 is replaced by serine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |